NGEN stock news · NervGen Pharma
Get alerts for NGEN
Follow NervGen Pharma (NGEN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NGENFree on the App Store and Google Play, or on the web.
NervGen Pharma shared its Q3 2026 results and said its NVG-291 drug got FDA Breakthrough Therapy status.
Good for NGENNervGen's Phase 3 study is advancing, with results expected in the first half of 2028. Cash should last until then, and the FDA designation makes this a positive update.